Upfront dabrafenib plus trametinib supported for paediatric low-grade glioma
First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
DOPA decarboxylase: a ‘highly promising’ biomarker for Parkinsonian disorders
DOPA decarboxylase could be an effective biomarker for dopaminergic dysfunction, detecting early and preclinical Lewy body disease and atypical Parkinsonian disorders, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Complete remission best for tapering SLE treatment
To prevent systemic lupus erythematosus flare, tapering of corticosteroid or immunosuppressive therapy is best done when patients are in complete remission and have maintained stable disease for at least 6 months, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Mezigdomide plus dexamethasone show ‘preliminary efficacy’ for refractory multiple myeloma
Phase 1–2 trial findings indicate that the cereblon E3 ubiquitin ligase modulator mezigdomide, given in combination with dexamethasone, could offer a novel oral regimen for patients with heavily pretreated multiple myeloma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Four distinct Kawasaki disease subgroups identified
Distinct subgroups exist among children with Kawasaki disease, say researchers in findings that provide some clues to the clinical variability of the disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cushing’s syndrome comorbidities require surveillance beyond remission
Experts emphasize the need for long-term surveillance for all patients with Cushing’s syndrome, after their systematic literature review showed associated comorbidities often continue well beyond remission.
Second primary malignancy risk after lymphoma chemotherapy and HSCT determined
Danish researchers have quantified the risk of second primary malignancy in patients with lymphoma who are treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Raised neutrophil count linked to amyotrophic lateral sclerosis onset
Increased neutrophil levels may be associated with an increased risk of developing amyotrophic lateral sclerosis, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intra-arterial chemotherapy approach shows promise for advanced unilateral retinoblastoma
The likelihood of successful globe salvage for children with advanced unilateral retinoblastoma is higher with intra-arterial chemotherapy than with a conventional intravenous approach, randomised trial findings suggest.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Base-edited CAR T-cell therapy shows promise for relapsed, refractory childhood ALL
Base-edited chimeric antigen receptor T-cell therapy is feasible for the treatment of relapsed or refractory childhood T-cell acute lymphoblastic leukemia, suggests research published in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
